Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.

Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, Stoltzfus J, Noureddin M, Serti E, Feld JJ, Liang TJ, Rotman Y, Rehermann B.

Hepatology. 2012 Jan;55(1):39-48. doi: 10.1002/hep.24628. Epub 2011 Nov 14.

2.

Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts).

Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R.

Clin Ter. 2006 Sep-Oct;157(5):457-68. Review. Retraction in: Clin Ter. 2008 May-Jun;159(3):208.

PMID:
17147054
3.

Natural killer cells in hepatitis C: Current progress.

Yoon JC, Yang CM, Song Y, Lee JM.

World J Gastroenterol. 2016 Jan 28;22(4):1449-60. doi: 10.3748/wjg.v22.i4.1449. Review.

4.

Recent advances in the anti-HCV mechanisms of interferon.

Huang M, Jiang JD, Peng Z.

Acta Pharm Sin B. 2014 Aug;4(4):241-7. doi: 10.1016/j.apsb.2014.06.010. Epub 2014 Jul 14. Review.

5.

Natural killer cells: multifaceted players with key roles in hepatitis C immunity.

Golden-Mason L, Rosen HR.

Immunol Rev. 2013 Sep;255(1):68-81. doi: 10.1111/imr.12090. Review.

6.

The natural killer cell response to HCV infection.

Ahlenstiel G.

Immune Netw. 2013 Oct;13(5):168-76. doi: 10.4110/in.2013.13.5.168. Epub 2013 Oct 26. Review.

7.

Perioperative IFN-alpha to avoid surgically induced immune suppression in colorectal cancer patients.

Oosterling SJ, van der Bij GJ, Mels AK, Beelen RH, Meijer S, van Egmond M, van Leeuwen PA.

Histol Histopathol. 2006 Jul;21(7):753-60. doi: 10.14670/HH-21.753. Review.

PMID:
16598674
8.

Cytokine therapeutics: lessons from interferon alpha.

Gutterman JU.

Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198-205. Review.

Supplemental Content

Support Center